Clinical Research
Copyright ©The Author(s) 2004.
World J Gastroenterol. Feb 1, 2004; 10(3): 415-418
Published online Feb 1, 2004. doi: 10.3748/wjg.v10.i3.415
Figure 1
Figure 1 Expression of survivin in cholangiocarcinoma (× 200, SP).
Figure 2
Figure 2 Expression of survivin in a human cholangiocarcinoma cell line. β-actin served as control. M: DL2000 marker, 1: Normal Qbc939, 2: 24 h after adding doxorubicin, 3: 48 h after adding doxorubicin.
Figure 3
Figure 3 Expression of survivin in a human cholangiocarcinoma cell line. 1 and 2: Normal Qbc939, 3: 24 h after adding doxorubicin, 4: 48 h after adding doxorubicin.